Abstract:e16513 Background: Anti-PD-1 based therapies have been standard-of-care options in both the front-line and treatment refractory settings in RCC, but only 20%~60% of patients respond to ICBs. Current biomarkers often fail to predict benefit of ICBs, so new reliable biomarkers are urgently warranted. Methods: Genomic and transcriptomic data were collected from 3 different ICB-treated RCC cohorts, including Miao et al. (n=53, WES), CheckMate (CM, n=261, WES; n=181, RNA-Seq) and JAVELIN (n=354, RNA-Seq) cohorts. Hallmark pathways downloaded from MSigDB database were used to screened for defective pathways that correlated with PFS using WES data of Miao et al. and CM cohorts. A defective pathway was defined as detecting at least one variant. Enrichment scores were calculated using RNA-seq data of CM cohort based on 28 immune cells gene sets provided by Charoentong et al. Immune cell signatures (ICSs) related to PFS were screened out using cox regression analysis. The selected pathways and ICSs were combined to develop a logistic regression model (10-fold cross-validation) to predict prognosis. Gene expression profiles of CM cohort were randomly split into two groups: 70% as the training set, and the remaining 30% as the test set. The predictive performance was validated in JAVELIN cohort independently. Gene sets expression levels were estimated using ssGSEA and NES methods. ROC curves were used to evaluate the predictive accuracy for 6-month PFS. Survival plots were created using the Kaplan-Meier estimator, and data were analyzed by log-rank test. Results: 7 signatures were selected as input features including 4 pathways (DNA_repair, IFN_alpha, EMT and angiogenesis) identified in Miao et al. and CM cohorts, together with 3 ICSs (Activated.CD4.T.cell, Activated.CD8.T.cell, and Immature.dendritic.cell) identified in CM cohort. Our model showed promising results for predicting 6-month PFS in CM dataset with AUC of 0.984 in the training set and 0.893 in the test set. The prediction of our model outperformed that based on TMB (AUC 0.655 vs. 0.587), GEP (AUC 0.746 vs. 0.823) and PD-L1 (AUC 0.823 vs. 0.768) both in the training and test sets, while combining our model with biomarkers above improved the prediction drastically with AUC of 0.996 in the training set and 0.935 in the test set. Meanwhile, our model maintained preferable performance for differentiating longer PFS from shorter PFS with p vale of 0.021 in JAVELIN cohort. Conclusions: We proposed a risk model to predict prognosis, in which feature selection based on hallmark pathways and immune cell subtypes. Our model showed excellent performance in predicting PFS in RCC patients undergoing immunotherapy, outperforming other ICB-related biomarkers. While combining our model with TMB, GEP, and PD-L1 was correlated more strongly with survival.

A Cancer Associated Fibroblasts-Related Six-Gene Panel for Anti-PD-1 Therapy in Melanoma Driven by Weighted Correlation Network Analysis and Supervised Machine Learning

Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis.

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Exploring a Specialized Programmed-Cell Death Patterns to Predict the Prognosis and Sensitivity of Immunotherapy in Cutaneous Melanoma Via Machine Learning.

Longitudinal High-Dimensional Analysis Identifies Biomarkers of Response to Anti-PD-1 Immunotherapy

Identification and targeting of cancer-associated fibroblast signature genes for prognosis and therapy in Cutaneous melanoma

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma

Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy

Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules

A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer

Data from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma

Immune Infiltration and Clinical Significance Analyses of the Cancer-Associated Fibroblast-Related Signature in Skin Cutaneous Melanoma

A CD8+ T cell-associated immune gene panel for prediction of the prognosis and immunotherapeutic effect of melanoma

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-Pd-(l)1 Therapies in NSCLC.

Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration with Gene Co-Expression Network in Pancreatic Adenocarcinoma.

Immune-related Genes and Gene Sets for Predicting the Response to Anti-Programmed Death 1 Therapy in Patients with Primary or Metastatic Non-Small Cell Lung Cancer

Weighted Gene Co-expression Network Analysis Identifies a Cancer-Associated Fibroblast Signature for Predicting Prognosis and Therapeutic Responses in Gastric Cancer

Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis

Association of a deep learning system with progression-free survival (PFS) in patients with renal cell carcinoma (RCC) treated with immune checkpoint blockades (ICBs).